By the cross priming of effector CD8+ T cells, the simultaneous delivery of SIRPα and doxorubicin, an immunogenic cell death (ICD)-inducer, achieved potent tumor growth inhibition in a melanoma model and even against tumor rechallenge in a colon cancer model. The gene discussed is CD8A; the disease is neoplasm.